Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Scientists working in the iPSC culture suite at the University of Oxford. This technology is available to the DPUK Stem Cells Network institutions. © Anna Lukala

All participants will have at baseline very extensive clinical and biological assessments, including detailed cognitive measures and biological measures of pathology (the latter including both amyloid and tau PET, and molecular assays of both of these in the cerebrospinal fluid). All participants are approached for consent to donate cells for iPSC stem cell generation, and all give consent for follow up from electronic health records and other linked data.

The hypothesis to be tested is whether the cellular phenotype (what the cells look like) of iPSC-derived neurons from patients will reflect the clinical phenotyping using an extensively ‘deep phenotyped’ Alzheimer’s cohort.